Phase 3 Readout~month

Phase 3 Topline: A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Azetukalner in Maj

Indication
Major Depressive Disorder

Other upcoming events for XENE

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner i
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, To
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, T
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner i
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Azetukalner in Maj — XENE Phase 3 Readout | BioSniper